Updated:
Neuro Technology Investors
Neuro Technology Investors was established by the O'Neil family, whose wealth originated from the O'Neil family's involvement in the automotive industry...
Neuro Technology Investors
Neuro Technology Investors was established by the O'Neil family, whose wealth originated from the O'Neil family's involvement in the automotive industry via the former O'Neil family office (The O'Neil Family Office). The firm is based in Arlington, Virginia, and is known for focusing exclusively on neurotechnology, including brain-computer interfaces, neuromodulation devices, and neurodiagnostic tools. The firm invests across multiple asset classes: venture capital, direct equity, and structured debt, targeting early-stage and growth-stage companies. Its portfolio includes holdings in Blackrock Neurotech, a leader in neural interfaces, and NeuroPace, a developer of responsive neurostimulation systems. Neuro Technology Investors also participates in syndicated rounds alongside institutional venture firms like Andreessen Horowitz. The firm's geographic focus is primarily North America, with selective exposure to European neurotech startups. Deployment activity in the last 24 months includes participation in a $40 million Series C round for Blackrock Neurotech (per the firm's official communications, 2024). The team size remains undisclosed, with key personnel including Managing Partner Thomas F. O'Neil III and Chief Investment Officer John R. Phillips, who oversees day-to-day deal operations. The firm maintains a relationship with the O'Neil Family Office philanthropic foundation, which funds research into neurological disorders. A structural differentiator is Neuro Technology Investors' narrow mandate: it is one of the few family offices solely dedicated to neurotechnology. This specialization provides domain-specific expertise in regulatory pathways and clinical validation, enabling the firm to source proprietary deal flow from academic institutions and NIH spinouts. The firm does not operate as a generalist investor, distinguishing it from multi-family offices or large venture funds.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Arlington
Corporate office
Arlington, VA, United States
Principals
Thomas F. O'Neil III
Managing Partner
John R. Phillips
Chief Investment Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Neuro Technology Investors?
Investment decisions are led by Managing Partner Thomas F. O'Neil III, with Chief Investment Officer John R. Phillips responsible for sourcing and evaluating deals. The team operates with a focused mandate in neurotechnology.
How does Neuro Technology Investors source proprietary deal flow?
The firm sources deals through direct outreach to academic research labs, partnerships with teaching hospitals, and relationships with NIH-funded spinouts. It also co-invests with venture firms like Andreessen Horowitz in syndicated rounds.
Is Neuro Technology Investors structured as a single family office or a multi-family office?
It is structured as a single family office for the O'Neil family, focused exclusively on neurotechnology. It does not manage funds for outside families.
What investment stages does Neuro Technology Investors typically target?
The firm targets early-stage and growth-stage neurotechnology companies, making equity investments in Series A through C rounds. It also structures debt for later-stage companies with approved devices.
Which sectors does Neuro Technology Investors explicitly avoid?
The firm avoids all non-neurotechnology sectors, including real estate, energy, and consumer goods. It also steers clear of biopharma and diagnostics that do not involve neural interfaces or neuromodulation.
Where does the underlying wealth come from?
The underlying wealth originates from the O'Neil family's involvement in the automotive industry, as part of The O'Neil Family Office structure.
Does Neuro Technology Investors maintain philanthropic structures?
Yes, the firm is linked to a philanthropic foundation that funds research into neurological disorders and emerging neurotechnology, separating its commercial investments from grant-making.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: